Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Latest News on BMY

Mar 25, 2025, 10:22 AM EDT - 11 hours ago

Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold

Mar 24, 2025, 8:48 AM EDT - 1 day ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS XRAY

Mar 21, 2025, 7:21 AM EDT - 4 days ago

Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy

MRK

Mar 19, 2025, 9:00 AM EDT - 6 days ago

10 Undervalued Dividend Growth Stocks: March 2025

MGA O PFE PRU TGT TROW UPS

Mar 18, 2025, 5:09 PM EDT - 7 days ago

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 14, 2025, 11:24 AM EDT - 11 days ago

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

TSVT

$Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma$

Mar 14, 2025, 6:59 AM EDT - 11 days ago

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Mar 13, 2025, 6:59 AM EDT - 12 days ago

Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

Mar 12, 2025, 5:46 PM EDT - 13 days ago

Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)

Mar 11, 2025, 3:31 PM EDT - 14 days ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

TSVT

Mar 11, 2025, 10:17 AM EDT - 14 days ago

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

TSVT

Mar 11, 2025, 7:17 AM EDT - 14 days ago

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

TSVT

Mar 10, 2025, 10:17 PM EDT - 14 days ago

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

TSVT

Mar 10, 2025, 6:19 PM EDT - 15 days ago

Final Trade: VRSK, BMY, VZ, APO, GM

GM APO VRSK

Mar 10, 2025, 12:54 PM EDT - 15 days ago

Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Mar 8, 2025, 9:01 AM EST - 17 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Mar 8, 2025, 8:00 AM EST - 17 days ago

I'm Locking 9-11% FCF Yields On These Dividend Icons

ARE

Mar 7, 2025, 6:59 AM EST - 18 days ago

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Mar 6, 2025, 6:35 PM EST - 19 days ago

Final Trade: SBUX, GAP, SLV, BMY

GAP SBUX SLV

Mar 4, 2025, 6:14 PM EST - 21 days ago

Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)

Mar 4, 2025, 1:45 AM EST - 21 days ago

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

EVO

Mar 3, 2025, 4:16 PM EST - 22 days ago

Bristol Myers Squibb Announces Dividend

Feb 25, 2025, 6:59 AM EST - 4 weeks ago

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Feb 24, 2025, 12:24 PM EST - 4 weeks ago

Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review

Feb 24, 2025, 7:30 AM EST - 4 weeks ago

Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here

ABBV AM AMZN CSL GOOG GOOGL LMT

Feb 24, 2025, 6:59 AM EST - 4 weeks ago

U.S.

Feb 21, 2025, 3:36 PM EST - 4 weeks ago

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 20, 2025, 12:49 AM EST - 4 weeks ago

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

Feb 19, 2025, 8:09 AM EST - 4 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

OGN PFE

Feb 19, 2025, 6:59 AM EST - 4 weeks ago

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Feb 16, 2025, 7:53 AM EST - 5 weeks ago

Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills

AG BBY EQR ETR FRT KEY KIM

Feb 16, 2025, 6:59 AM EST - 5 weeks ago

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Feb 13, 2025, 4:16 PM EST - 5 weeks ago

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Feb 10, 2025, 10:41 AM EST - 6 weeks ago

What's Going On With Bristol Myers Squibb Stock On Monday?

Feb 10, 2025, 8:15 AM EST - 6 weeks ago

Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook

$Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma$